Bioavailability of Digoxin
Authors:
- Trieste G. VittiTVTrieste G. Vitti
- Daniel BanesDBDaniel Banes
- Theodore E. ByersTBTheodore E. Byers
- 16 December 1971
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 285 (25) , 1433-1434
Abstract
A variable or poor response to a therapeutic agent may not have its origin in the patient; it may be due to a formulation defect in the drug product administered. The most commonly recognized formulation defect in a dosage form such as a tablet is a deficiency or excess of the active ingredient. The fact that difficulties of this type were occurring with certain lots of digoxin and digitoxin tablets on the market was discovered by the Food and Drug Administration through a systematic testing program inaugurated in April, 1970, by the Bureau of Drugs with the testing done at . . .Keywords
This publication has 2 references indexed in Scilit:
- Variation in Biologic Availability of Digoxin from Four PreparationsNew England Journal of Medicine, 1971
- Determination of Therapeutic and Toxic Serum Digoxin Concentrations by RadioimmunoassayNew England Journal of Medicine, 1969